Mestinon Vs. Neostigmine Methylsulfate for a female patient aged 32 - from FDA reports


Summary

This is a personalized comparison Mestinon, Neostigmine Methylsulfate for a woman aged 32. The study is created by eHealthMe based on reports from FDA.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>



On May, 19, 2017

186 females aged 32 (±5) who take Mestinon, Neostigmine Methylsulfate are studied.

Number of reports submitted per year:

Mestinon, Neostigmine Methylsulfate for a female patient aged 32.

Information of the patient in this study:

  • Age: 32
  • Gender: female
  • Reason for the study: None

Drugs in this study:

  • Mestinon (pyridostigmine bromide)
  • Neostigmine Methylsulfate (neostigmine methylsulfate)

eHealthMe real world results for females aged 32 (±5):

Most common side effects:

Mestinon:
  • Diarrhea
  • Dizziness
  • Fatigue
  • Headache
  • High Blood Pressure
  • Myasthenia Gravis
  • Nausea
  • Photophobia
  • Rashes
  • Weakness
Neostigmine Methylsulfate:
  • Arrhythmias
  • Breathing Difficulty
  • Heart Rate Increased
  • Hypotension
  • Liver Function Test Abnormal
  • Mental Status Changes Postoperative
  • Pulmonary Embolism
  • Respiratory Acidosis
  • Sepsis
  • Unresponsive To Stimuli

Most common side effects experienced by people in long term use:

Mestinon:
Neostigmine Methylsulfate:

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

You can also:

What are the drugs?

Related studies:

Can you answer these questions?

More questions for: Mestinon, Neostigmine methylsulfate

You may be interested in these reviews

More reviews for: Mestinon, Neostigmine methylsulfate